Drug Target Review

APRIL 12, 2024

Starting from a single cell rather than bulk cells eliminates the need for post-transfection cell sorting, saving hands-on time and ensuring 100 percent monoclonality. This holds particular significance, as it is a prerequisite for FDA approval in biotechnology that any cell clones must originate from a single-cell progenitor.

Cell Biology 105

Cell Biology FDA Approval FDA Research 105

Drug Target Review

APRIL 12, 2024

Starting from a single cell rather than bulk cells eliminates the need for post-transfection cell sorting, saving hands-on time and ensuring 100 percent monoclonality. This holds particular significance, as it is a prerequisite for FDA approval in biotechnology that any cell clones must originate from a single-cell progenitor.

Cell Biology 98

Cell Biology FDA Approval FDA Research 98

Drug Target Review

JUNE 5, 2023

As such, our team remains on track to complete our 5×5 strategy – laid out in October 2022 – by harnessing our technology and resources to continue efficiently growing Zymeworks’ pipeline of in-house and partnered candidates. Author Bio: Paul Moore, PhD Dr Moore joined Zymeworks in July 2022 as Chief Scientific Officer.

Treatment 100

Treatment Pharmacokinetics Drugs Cell Biology 100

Drug Target Review

SEPTEMBER 19, 2023

In spite of current success and possibility to be a successful cell technology model, the integration of organ-on-chips into drug development process needs more optimisation to be validated for FDA approval. From 3D cell culture to organs-on-chips. Trends in Cell Biology. 2010;328(5986):1662-8. Ingber DE.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

Codon

APRIL 2, 2023

An open-source FACS automation system for high-throughput cell biology. Read Eisai and Biogen — companies behind the controversial, FDA-approved drug for Alzheimer’s, called Aduhelm — have published three additional papers with “detailed analyses” from their phase 2 trials. Might be useful!

DNA 52

DNA RNA Engineering Licensing 52

Drug Target Review

JANUARY 16, 2025

Macrocycles, by contrast, have a higher degree of cell permeability and are also capable of binding to protein surface sites due to their size and flexibility. 6 Among the well-known FDA-approved macrocyclic drugs are those that treat Hepatitis C, a disease with previously limited therapeutic options.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52